Dipanjan Debnath

Dr. Dipanjan Debnath


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DDDipanjan Debnath
Dipanjan Debnath
HAHassan Abdulahi
Hassan Abdulahi
AAAbigail Arrigo
Abigail Arrigo
MDMadhurima Debnath
Madhurima Debnath
KDKriti Dhamija
Kriti Dhamija
GFGene Finley
Gene Finley
Concurrent chemoradiation (cCRT) is standard for unresectable, locally advanced non–small cell lung cancer (NSCLC), but the preferred concurrent chemotherapy backbone is uncertain. Cisplatin–etoposide (EP) and weekly carboplatin–paclitaxel (PC) are commonly used. Background/Objectives: Retrospective single-institution cohort of adults with histologically confirmed, inoperable AJCC stage II–III NSCLC treated 2015–2023 with definitive thoracic radiation plus concurrent EP or PC. Methods: We collected clinical characteristics, treatment completion, best radiographic response, adverse events (AEs), progression, and death. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints were overall response rate (ORR) and AEs. Kaplan–Meier survival estimates were generated and compared using log-rank testing; hazard ratios (HRs) were estimated using Cox proportional hazards models. Results: Among 177 patients (EP, n = 43; PC, n = 134), stage III disease comprised 91% in the EP cohort and 90% in the PC cohort. ORR favored EP (63% vs 52%), and primary progressive disease as best response was less frequent with EP (7% vs 21%, p = 0.04). Median PFS was 48.07 vs 14.93 months (HR 0.65, 95% CI 0.43–0.90; p = 0.05). Median OS numerically favored EP (76.97 vs 34.60 months; HR 0.70, 95% CI 0.44–1.12; p = 0.17). Any-grade AEs occurred at similar rates (34.9% vs 34.3%), whereas grade 3–4 AEs were more frequent with EP (25.6% vs 9.7%; p = 0.02). Conclusion: EP-based cCRT was associated with longer PFS and higher grade 3–4 toxicity than PC; findings support individualized selection and need validation, especially in the immunotherapy era.